Overview of This Study:
This market research study involved the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global in situ hybridization market.
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify critical qualitative and quantitative information and to assess market prospects. The size of the ISH market was estimated through various secondary research approaches and triangulated with inputs from primary research to arrive at the final market size.
Download PDF Brochure@
Research Methodologies Followed:
The secondary sources referred to for this research study include publications from government sources, such as WHO, OECD, GLOBOCAN, CDC, World Bank, and World Cancer Research Fund International. Secondary sources also include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global ISH market, which was validated through primary research.
Extensive primary research was conducted after acquiring basic knowledge about the global in situ hybridization market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (such as personnel from the pharmaceutical and biopharmaceutical industry) and supply-side (such as C-level and D-level executives, product managers, marketing and sales managers of key manufacturers, distributors, and channel partners, among others) across four major regions—North America, Europe, the Asia Pacific, and the Rest of the World.
Approximately 80% and 20% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
Expected Revenue Gain, Globally:
The global in situ hybridization market size is projected to reach USD 1.3 billion by 2025 from USD 0.9 billion in 2020, at a CAGR of 7.4% during the forecast period.
Growth Boosting Factors:
The increasing incidence and prevalence of cancer and genetic disorders and awareness about companion diagnostics tests in ISH are the major factors driving the growth of this market.
Challenge: Lack of skilled professionals
To conduct an ISH-based test, it is very crucial to understand the molecular information of a chromosome or a gene. In addition, the reluctance to move from manual operations to automation is another challenge for market growth. Many providers find it challenging to make the transition to IT-based approaches from manual or traditional methods, or may not prefer to make the shift at all. Thus, the shortage of skilled, well-trained, and technically knowledgeable laboratory technicians to conduct ISH-based diagnosis is limiting their overall adoption, particularly in emerging markets.
Opportunity: Untapped markets in developing countries
In developed countries, high-quality molecular diagnostic tests are readily available. However, in developing countries, the cost of these diagnostic technologies is very high, which often makes them unaffordable for a large part of the population. Moreover, the lack of a commercial market for diagnostic procedures has resulted in the availability of a small number of diagnostic tests in developing countries.
North America accounted for the largest share of the global ISH market in 2019.
In 2019, North America accounted for the largest share of the ISH market. The increasing incidence of cancer and infectious diseases in the region is driving the focus on the development of personalized medicine and diagnostics tests. As a result, due to the strong demand for early cancer detection capabilities, the market for ISH-based diagnostic tests is expected to see steady growth. In addition, the region is home to a large base of clinical research laboratories and academic institutes.
Request Sample Pages@
Some of the key players include Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (US) Danaher Corporation (US), Thermofisher Scientific (US), Abnova Corporation (Taiwan), BioGenex Laboratories (US), Bio-Techne Corporation (US), Biocare Medical, and Bio SB (US)